Physician profile
Inder P Singal
NPI 1922082072
$9,264.22
in general payments reported to CMS, 2019-2025
21 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $852 · 2020: $5,152 · 2021: $241 · 2022: $615 · 2023: $989 · 2024: $966 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367 · Education: $37.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,366.90 |
| Education | $37.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $5,949.14 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $691.83 | 2019-2025 | Clareon, Argos |
| Genentech USA, INC. | $645.84 | 2019-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $291.39 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $281.41 | 2023-2025 | Syfovre |
| Abbvie INC. | $209.72 | 2022-2025 | Alphagan P, Lumigan |
| Ani Pharmaceuticals, INC. | $203.60 | 2022-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Allergan, INC. | $168.59 | 2019-2022 | |
| Biogen, INC. | $155.04 | 2022-2023 | |
| Astellas Pharma US INC | $121.14 | 2023-2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $100.31 | 2021-2023 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $97.47 | 2019-2021 | |
| Genentech, INC. | $95.83 | 2022 | |
| Glaukos Corporation | $55.24 | 2019 | |
| Alimera Sciences, INC. | $45.18 | 2024 | Iluvien, Yutiq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $44.32 | 2024 | |
| Oyster Point Pharma, INC. | $32.46 | 2022-2025 | Tyrvaya |
| Harrow Eye, LLC | $23.44 | 2025 | Triesence |
| Horizon Therapeutics Plc | $19.13 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $17.15 | 2020 | |
| Ivantis, INC | $15.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inder Singal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.